» Articles » PMID: 19636084

The Dosimetric Feasibility of Gold Nanoparticle-aided Radiation Therapy (GNRT) Via Brachytherapy Using Low-energy Gamma-/x-ray Sources

Overview
Journal Phys Med Biol
Publisher IOP Publishing
Date 2009 Jul 29
PMID 19636084
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

The preferential accumulation of gold nanoparticles within tumors and the increased photoelectric absorption due to the high atomic number of gold cooperatively account for the possibility of significant tumor dose enhancement during gold nanoparticle-aided radiation therapy (GNRT). Among the many conceivable ways to implement GNRT clinically, a brachytherapy approach using low-energy gamma-/x-ray sources (i.e. E(avg) < 100 keV) appears to be highly feasible and promising, because it may easily fulfill some of the technical and clinical requirements for GNRT. Therefore, the current study investigated the dosimetric feasibility of implementing GNRT using the following sources: (125)I, 50 kVp and (169)Yb. Specifically, Monte Carlo (MC) calculations were performed to determine the macroscopic dose enhancement factors (MDEF), defined as the ratio of the average dose in the tumor region with and without the presence of gold nanoparticles during the irradiation of the tumor, and the photo/Auger electron spectra within a tumor loaded with gold nanoparticles. The current study suggests that a significant tumor dose enhancement (e.g. >40%) could be achievable using (125)I, 50 kVp and (169)Yb sources and gold nanoparticles. When calculated at 1.0 cm from the center of the source within a tumor loaded with 18 mg Au g(-1), macroscopic dose enhancement was 116, 92 and 108% for (125)I, 50 kVp and (169)Yb, respectively. For a tumor loaded with 7 mg Au g(-1), it was 68, 57 and 44% at 1 cm from the center of the source for (125)I, 50 kVp and (169)Yb, respectively. The estimated MDEF values for (169)Yb were remarkably larger than those for (192)Ir, on average by up to about 70 and 30%, for 18 mg Au and 7 mg Au cases, respectively. The current MC study also shows a remarkable change in the photoelectron fluence and spectrum (e.g. more than two orders of magnitude) and a significant production (e.g. comparable to the number of photoelectrons) of the Auger electrons within the tumor region due to the presence of gold nanoparticles during low-energy gamma-/x-ray irradiation. The radiation sources considered in this study are currently available and tumor gold concentration levels considered in this investigation are deemed achievable. Therefore, the current results strongly suggest that GNRT can be successfully implemented via brachytherapy with low energy gamma-/x-ray sources, especially with a high dose rate (169)Yb source.

Citing Articles

Significance of the proton energy loss mechanism to gold nanoparticles in proton therapy: a Geant4 simulation.

Tabbakh F Sci Rep. 2024; 14(1):24978.

PMID: 39443616 PMC: 11499847. DOI: 10.1038/s41598-024-76244-w.


Zinc-Modified Titanate Nanotubes as Radiosensitizers for Glioblastoma: Enhancing Radiotherapy Efficacy and Monte Carlo Simulations.

Diz F, Monteiro W, Silveira I, Ruano D, Zotti E, Weimer R ACS Omega. 2024; 9(27):29499-29515.

PMID: 39005768 PMC: 11238320. DOI: 10.1021/acsomega.4c02125.


Nanoscale gold nanoparticle (GNP)-laden tumor cell model and its use for estimation of intracellular dose from GNP-induced secondary electrons.

Jayarathna S, Kaphle A, Krishnan S, Cho S Med Phys. 2024; 51(9):6276-6291.

PMID: 38935922 PMC: 11489034. DOI: 10.1002/mp.17275.


Innovative therapeutic strategies to overcome radioresistance in breast cancer.

Arnold C, Mangesius J, Portnaia I, Ganswindt U, Wolff H Front Oncol. 2024; 14:1379986.

PMID: 38873260 PMC: 11169591. DOI: 10.3389/fonc.2024.1379986.


A High-Sensitivity Benchtop X-Ray Fluorescence Emission Tomography (XFET) System With a Full-Ring of X-Ray Imaging-Spectrometers and a Compound-Eye Collimation Aperture.

Mandot S, Zannoni E, Cai L, Nie X, La Riviere P, Wilson M IEEE Trans Med Imaging. 2024; 43(5):1782-1791.

PMID: 38696285 PMC: 11129545. DOI: 10.1109/TMI.2023.3348791.


References
1.
Dawson P, Penhaligon M, Smith E, Saunders J . Iodinated contrast agents as "radiosensitizers". Br J Radiol. 1987; 60(710):201-3. DOI: 10.1259/0007-1285-60-710-201. View

2.
Gutman G, Sozontov E, Strumban E, Yin F, Lee S, Kim J . A novel needle-based miniature x-ray generating system. Phys Med Biol. 2004; 49(20):4677-88. DOI: 10.1088/0031-9155/49/20/001. View

3.
Diagaradjane P, Orenstein-Cardona J, Colon-Casasnovas N, Deorukhkar A, Shentu S, Kuno N . Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res. 2008; 14(3):731-41. DOI: 10.1158/1078-0432.CCR-07-1958. View

4.
Roeske J, Nunez L, Hoggarth M, Labay E, Weichselbaum R . Characterization of the theorectical radiation dose enhancement from nanoparticles. Technol Cancer Res Treat. 2007; 6(5):395-401. DOI: 10.1177/153303460700600504. View

5.
Robar J . Generation and modelling of megavoltage photon beams for contrast-enhanced radiation therapy. Phys Med Biol. 2006; 51(21):5487-504. DOI: 10.1088/0031-9155/51/21/007. View